A Phase 4 interventional study of Chlorambucil and Cyclophosphamide in Lymphocytic Leukemia, Chronic, sponsored by Hoffmann-La Roche. Terminated at 8 sites in Russian Federation. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2019-03-14.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell — 3 open to participants now, 11 under way, none of them phase 3. Cyclophosphamide · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 104th largest by enrollment of the 145 interventional ones that give a count, is one of 8 that started in 2011, is one of 3 in phase 4, and was the 112th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →3 of the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Medical University of South Carolina · Sites in United States
Ages 18+
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages up to 75
By country, each count listing its studies:
Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
155 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 114 · Phase 3 11 · Phase 4 3
First in 1988; this study’s year is marked. 8 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 49 across the 145 interventional studies. Of the 132 that completed or were terminated, 77 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 155 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche: 1 open now, 2 under way, none of them phase 3. Of 46 finished, 28 (61%) have results posted.
Among the 48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche, this one is the 33rd largest by enrollment of the 36 interventional ones that give a count, is one of 8 that started in 2011, is one of 3 in phase 4, and was the 18th registered.
Hoffmann-La Roche’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2003.
4 of the studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00466531Memorial Sloan Kettering Cancer CenterTreatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 | 2026-12 |
| NCT06001385Center for International Blood and Marrow Transplant ResearchHLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | 2026-12-24 |
| NCT02153580City of Hope Medical CenterCellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia | 2027-08-11 |
| NCT05805605Masonic Cancer Center, University of MinnesotaAllo HSCT Using RIC and PTCy for Hematological Diseases | 2027-10-22 |
Add all 4 to your calendar (.ics) → With an account.
Among the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among Hoffmann-La Roche’s 48 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
This multi-center, randomized study compared the efficacy and safety of MabThera (rituximab) in combination with either fludarabine and cyclophosphamide or with chlorambucil in participants with previously untreated B-cell chronic lymphocytic leukemia and unfavorable somatic status. Participants were randomized to receive Mabthera (375 mg/m2 intravenously [IV] Day 1 of Cycle 1, 500 mg/m2 IV Day 1 Cycles 2-6) with either fludarabine (20 mg/m2 IV or 32 mg/m2 orally Days 1-3) and cyclophosphamide (150 mg/m2 IV or orally Days 1-3) or with chlorambucil (10 mg/m2 orally Days 1-7) for 6 cycles of 28 days. Anticipated time on study treatment was 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rituximab, fludarabine, and cyclophosphamide
Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Rituximab
Rituximab and chlorambucile
Drug: Chlorambucil · Drug: Rituximab
10 mg/m\^2 orally on Days 1-7 of each 28-day cycle for 6 cycles
150 mg/m\^2 IV or orally on Days 1-3 of each 28-day cycle for 6 cycles
20 mg/m\^2 IV or 32 mg/m2 orally Days 1-3 of each 28-day cycle for 6 cycles
375 mg/m2 IV on Day 1 of Cycle 1; 500 mg/m2 IV on Day 1 of Cycles 2-6 (28-day cycles)
Also known as: MabThera
Percentage of Participants With Complete Remission
Complete remission was defined as the disappearance of all signs of disease.
Time frame: Up to approximately 5 years
Percentage of Participants With Disease Progression
Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen.
Time frame: Up to approximately 5 years
Percentage of Participants With Stable Disease
Stable disease was defined as not meeting the criteria for partial remission or disease progression
Time frame: Up to approximately 5 years
Percentage of Participants With Partial Remission
Partial remission was defined as a reduction in tumor size by \>50%.
Time frame: Up to approximately 5 years
Duration of Response
Duration of Response was defined as the time period from the last day of study treatment to the day when disease progression occurred in participants who previously had complete or partial remission. Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen. Complete remission was defined as the disappearance of all signs of disease. Partial remission was defined as a reduction in tumor size by \>50%.
Time frame: Up to approximately 5 years
Progression-free Survival
Progression-free survival was defined as the time period from the first day of study treatment to the day when disease progression occurred. Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen.
Time frame: Up to approximately 5 years
Event-free Survival
Event-free survival was defined as the time period from the first day of study treatment to occurrence of any of the following events: appearance of disease progression or relapse; prescription of a new treatment for disease relapse; death caused by B-cell chronic lymphocytic leukemia (B-CLL); or complications from B-CLL or therapy. Relapse was defined as disease progression in participants with complete or partial remission lasting at least 6 months after treatment completion. Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen. Complete remission was defined as the disappearance of all signs of disease. Partial remission was defined as a reduction in tumor size by \>50%.
Time frame: Up to approximately 5 years
Overall Survival
Overall survival was defined as the time period from the first day of study treatment to participant death.
Time frame: Up to approximately 5 years
Percentage of Participants With Phenotypic Remission
Phenotypic remission was considered achieved if a participant had a negative test for minimal residual disease. A negative test for minimal residual disease was defined as tumor cells ≤0.01% of the total number of peripheral leukocytes.
Time frame: Up to approximately 5 years
Percentage of Participants With Adverse Events (AEs) and Serious AEs
An AE was defined as any unfavorable medical occurrence in a participant receiving a study drug, regardless of relationship the study drug. An AE was considered serious if it met any of the following criteria: was fatal or life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was clinically significant and/or required an intervention to prevent any of the listed criteria.
Time frame: Up to approximately 5 years
| Milestone | FCR-lite | LR Therapy |
|---|---|---|
| Started | 10 | 16 |
| Completed | 2 | 4 |
| Not completed | 8 | 12 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Relapse of underlying disease | 1 | 3 |
| Withdrew: Progression of underlying disease | 2 | 7 |
| Withdrew: Reason not specified | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
Complete remission was defined as the disappearance of all signs of disease.
| percentage of participants | FCR-lite | LR Therapy |
|---|---|---|
| Percentage of Participants With Complete Remission | 42.9 | 18.8 |
Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen.
| percentage of participants | FCR-lite | LR Therapy |
|---|---|---|
| Percentage of Participants With Disease Progression | 0 | 6.3 |
Stable disease was defined as not meeting the criteria for partial remission or disease progression
| percentage of participants | FCR-lite | LR Therapy |
|---|---|---|
| Percentage of Participants With Stable Disease | 14.3 | 18.8 |
Partial remission was defined as a reduction in tumor size by \>50%.
| percentage of participants | FCR-lite | LR Therapy |
|---|---|---|
| Percentage of Participants With Partial Remission | 42.9 | 56.3 |
Duration of Response was defined as the time period from the last day of study treatment to the day when disease progression occurred in participants who previously had complete or partial remission. Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen. Complete remission was defined as the disappearance of all signs of disease. Partial remission was defined as a reduction in tumor size by \>50%.
| days | FCR-lite | LR Therapy |
|---|---|---|
| Duration of Response | NA (NA to NA) | NA (NA to NA) |
Progression-free survival was defined as the time period from the first day of study treatment to the day when disease progression occurred. Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen.
| days | FCR-lite | LR Therapy |
|---|---|---|
| Progression-free Survival | NA (NA to NA) | NA (NA to NA) |
Event-free survival was defined as the time period from the first day of study treatment to occurrence of any of the following events: appearance of disease progression or relapse; prescription of a new treatment for disease relapse; death caused by B-cell chronic lymphocytic leukemia (B-CLL); or complications from B-CLL or therapy. Relapse was defined as disease progression in participants with complete or partial remission lasting at least 6 months after treatment completion. Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen. Complete remission was defined as the disappearance of all signs of disease. Partial remission was defined as a reduction in tumor size by \>50%.
| days | FCR-lite | LR Therapy |
|---|---|---|
| Event-free Survival | 679 (14.00 to NA) | NA (NA to NA) |
Overall survival was defined as the time period from the first day of study treatment to participant death.
| days | FCR-lite | LR Therapy |
|---|---|---|
| Overall Survival | NA (NA to NA) | NA (NA to NA) |
Phenotypic remission was considered achieved if a participant had a negative test for minimal residual disease. A negative test for minimal residual disease was defined as tumor cells ≤0.01% of the total number of peripheral leukocytes.
| percentage of participants | FCR-lite | LR Therapy |
|---|---|---|
| Percentage of Participants With Phenotypic Remission | 25.0 | 30.0 |
An AE was defined as any unfavorable medical occurrence in a participant receiving a study drug, regardless of relationship the study drug. An AE was considered serious if it met any of the following criteria: was fatal or life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was clinically significant and/or required an intervention to prevent any of the listed criteria.
| percentage of participants | FCR-lite | LR Therapy |
|---|---|---|
| Non-serious AEs | 80.00 | 56.25 |
| Serious AEs | 20.00 | 18.75 |
Collected over Up to approximately 5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FCR-lite | — | 2/10 (20%) | 8/10 (80%) |
| LR Therapy | — | 3/16 (18.8%) | 9/16 (56.3%) |
| Event | FCR-lite | LR Therapy |
|---|---|---|
| DeathGeneral disorders | 2/10 | 0/16 |
| Acute myocardial infarctionVascular disorders | 1/10 | 0/16 |
| Retroperitoneal abscessInfections and infestations | 0/10 | 1/16 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 0/10 | 1/16 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 0/10 | 1/16 |
| Event | FCR-lite | LR Therapy |
|---|---|---|
| Neutrophil count decreasedInvestigations | 2/10 | 2/16 |
| BronchitisRespiratory, thoracic and mediastinal disorders | 2/10 | 1/16 |
| PyrexiaGeneral disorders | 2/10 | 0/16 |
| White blood cell count decreasedInvestigations | 1/10 | 2/16 |
| Blood bilirubin increasedInvestigations | 1/10 | 0/16 |
| Glomerular filtration rateInvestigations | 1/10 | 0/16 |
| Cardiac failure acuteCardiac disorders | 1/10 | 0/16 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/10 | 0/16 |
| NauseaGastrointestinal disorders | 1/10 | 0/16 |
| Renal colicRenal and urinary disorders | 1/10 | 0/16 |
| Age, Continuous(years) | FCR-lite | LR Therapy | Total |
|---|---|---|---|
| Mean | 68.7 ± 7.09 | 68.6 ± 4.95 | 68.6 ± 5.73 |
| Sex: Female, Male(Participants) | FCR-lite | LR Therapy | Total |
|---|---|---|---|
| Female | 3 | 7 | 10 |
| Male | 7 | 9 | 16 |
Ran from Apr 2011 to primary completion in Mar 2016, 58 months.
Results were first posted in Mar 2019, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cyclophosphamide · Fludarabine
Leukemia, Lymphocytic, Chronic, B-Cell →